Chromos will engineer cell lines for Genitope Mab using its ACE system.

Chromos Molecular Systems entered into a cell line engineering service agreement with Genitope to develop a cell line using Chromos’ ACE system for potential use in the clinical and commercial manufacture of a biopharmaceutical product.

Specifically, Chromos will engineer cell lines for the expression of a Mab for Genitope. According to Chromos, recent data generated by one of its partners has shown that cell lines engineered using ACE are capable of achieving Mab yields of greater than 4 g/L in a nonoptimized bioreactor system, a four-fold improvement over the partner’s original cell line.

Previous articleOmniViz and ChemAxon Extend Data Visualization and Analysis Agreement
Next articleCleveland BioLabs to Build Facility at Roswell Park to Aid Product R&D